Cargando…
Intradermal delivery of modified mRNA encoding VEGF-A in patients with type 2 diabetes
Chemically modified mRNA is an efficient, biocompatible modality for therapeutic protein expression. We report a first-time-in-human study of this modality, aiming to evaluate safety and potential therapeutic effects. Men with type 2 diabetes mellitus (T2DM) received intradermal injections of modifi...
Autores principales: | Gan, Li-Ming, Lagerström-Fermér, Maria, Carlsson, Leif G., Arfvidsson, Cecilia, Egnell, Ann-Charlotte, Rudvik, Anna, Kjaer, Magnus, Collén, Anna, Thompson, James D., Joyal, John, Chialda, Ligia, Koernicke, Thomas, Fuhr, Rainard, Chien, Kenneth R., Fritsche-Danielson, Regina |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6382754/ https://www.ncbi.nlm.nih.gov/pubmed/30787295 http://dx.doi.org/10.1038/s41467-019-08852-4 |
Ejemplares similares
-
Rapid Production of Human VEGF-A following Intradermal Injection of Modified VEGF-A mRNA Demonstrated by Cutaneous Microdialysis in the Rabbit and Pig In Vivo
por: Pehrsson, Susanne, et al.
Publicado: (2019) -
Safety, tolerability, pharmacokinetics and effect on serum uric acid of the myeloperoxidase inhibitor AZD4831 in a randomized, placebo‐controlled, phase I study in healthy volunteers
por: Gan, Li‐Ming, et al.
Publicado: (2019) -
Synthetic mRNA Encoding VEGF-A in Patients Undergoing Coronary Artery Bypass Grafting: Design of a Phase 2a Clinical Trial
por: Anttila, Vesa, et al.
Publicado: (2020) -
Initial Clinical Experience with AZD5718, a Novel Once Daily Oral 5‐Lipoxygenase Activating Protein Inhibitor
por: Ericsson, Hans, et al.
Publicado: (2018) -
VEGFA mRNA for regenerative treatment of heart failure
por: Collén, Anna, et al.
Publicado: (2021)